- Home
- KDLY vs LPCN Comparison
KDLY vs LPCN Comparison
Compare KDLY & LPCN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KDLY
- LPCN
- Stock Information
- Founded
- KDLY 2019
- LPCN 1997
- Country
- KDLY United States
- LPCN United States
- Employees
- KDLY N/A
- LPCN N/A
- Industry
- KDLY
- LPCN Biotechnology: Pharmaceutical Preparations
- Sector
- KDLY
- LPCN Health Care
- Exchange
- KDLY NYSE
- LPCN Nasdaq
- Market Cap
- KDLY 10.9M
- LPCN 16.1M
- IPO Year
- KDLY 2024
- LPCN N/A
- Fundamental
- Price
- KDLY $3.78
- LPCN $3.23
- Analyst Decision
- KDLY
- LPCN Strong Buy
- Analyst Count
- KDLY 0
- LPCN 1
- Target Price
- KDLY N/A
- LPCN $10.00
- AVG Volume (30 Days)
- KDLY 184.1K
- LPCN 10.5K
- Earning Date
- KDLY 05-13-2025
- LPCN 05-08-2025
- Dividend Yield
- KDLY N/A
- LPCN N/A
- EPS Growth
- KDLY N/A
- LPCN N/A
- EPS
- KDLY N/A
- LPCN N/A
- Revenue
- KDLY $2,719,840.00
- LPCN $3,674,834.00
- Revenue This Year
- KDLY N/A
- LPCN N/A
- Revenue Next Year
- KDLY N/A
- LPCN N/A
- P/E Ratio
- KDLY N/A
- LPCN N/A
- Revenue Growth
- KDLY N/A
- LPCN N/A
- 52 Week Low
- KDLY $0.65
- LPCN $2.75
- 52 Week High
- KDLY $5.25
- LPCN $11.79
- Technical
- Relative Strength Index (RSI)
- KDLY N/A
- LPCN 49.14
- Support Level
- KDLY N/A
- LPCN $3.12
- Resistance Level
- KDLY N/A
- LPCN $3.60
- Average True Range (ATR)
- KDLY 0.00
- LPCN 0.25
- MACD
- KDLY 0.00
- LPCN 0.02
- Stochastic Oscillator
- KDLY 0.00
- LPCN 38.80
About KDLY KINDLY MD INC
Kindly MD Inc is a holistically focused pain management clinic and healthcare data company. It offers direct health care to patients integrating prescription medicine and behavioral health services to reduce opioid use in the chronic pain patient population. Its specialty outpatient clinical services are offered on a subscription and fee-for-service basis to augment traditional healthcare. The Company offers evaluation and management, including, but not limited to chronic pain, functional medicine, cognitive behavioral therapy, recovery support services, overdose education efforts, peer support, limited urgent care, preventative medicine, travel services, and hormone therapy.
About LPCN Lipocine Inc.
Lipocine Inc is a clinical-stage biopharmaceutical company, that is engaged in research and development for the delivery of drugs using its proprietary delivery technology. Its principal operation is to provide oral delivery solutions for existing drugs. Lipocine develops its drug candidates or it develops drug candidates on behalf of or in collaboration with corporate partners. The company's product TLANDO is an oral testosterone replacement therapy ("TRT"). It also has other products in the pipeline such as LPCN 1144, TLANDO, TLANDO XR, LPCN 1148, LPCN 1107, LPCN 1154, and LIP'RAL7 Technology. The Company has a single reportable segment, research, and development for the delivery of drugs using its proprietary delivery technology.